| Chapter title |
Immunotherapy in Lung Cancer
|
|---|---|
| Chapter number | 10 |
| Book title |
Lung Cancer
|
| Published in |
Cancer treatment and research, January 2016
|
| DOI | 10.1007/978-3-319-40389-2_10 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-940387-8, 978-3-31-940389-2
|
| Authors |
Emily H. Castellanos, Leora Horn, Castellanos, Emily H., Horn, Leora |
| Abstract |
Lung cancer has not traditionally been viewed as an immune-responsive tumor. However, it is becoming evident that tumor-induced immune suppression is vital to malignant progression. Immunotherapies act by enhancing the patient's innate immune response and hold promise for inducing long-term responses in select patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immune checkpoint inhibitors, in particular, inhibitors to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) and programmed death receptor ligand 1 (PD-L1) have shown promise in early studies and are currently in clinical trials in both small cell lung cancer and non-small cell lung cancer patients. Two large randomized phase III trials recently demonstrated superior overall survival (OS) in patients treated with anti-PD-1 therapy compared to chemotherapy in the second-line setting. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 17% |
| Student > Master | 4 | 11% |
| Student > Postgraduate | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Other | 3 | 8% |
| Other | 6 | 17% |
| Unknown | 10 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 33% |
| Biochemistry, Genetics and Molecular Biology | 9 | 25% |
| Agricultural and Biological Sciences | 3 | 8% |
| Immunology and Microbiology | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 10 | 28% |